Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allopurinol added to standard care including hypothermia for neonatal hypoxic-ischemic brain injury
NL-OMON54639Phase 3Recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypoxic-ischemic encephalopathy (HIE) and asphyxia neonatorum comparing Allopurinol + standard care with Placebo + standard care (2 arms). Primary endpoints: Death and Severe neurodevelopmental impairment at 2 years. Started May 2018; status: recruiting.
02
Drugs
allopurinol
03
Conditions
hypoxic-ischemic encephalopathy (HIE)asphyxia neonatorum
Beyond the preview
Go deeper on NL-OMON54639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54639.